SCHEMBL2802299

SCHEMBL2802299

COc1cccc(NC(=O)N2CCc3c(cnc4[nH]ncc34)C2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
HTT P42858 3/20 0.52
FLT3 P36888 2/20 0.52
FAAH O00519 2/20 0.49
LMNA P02545 2/20 0.48
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GPR142 Q7Z601 5/20 0.47
PAK1 Q13153 1/20 0.47
KIT P10721 1/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
LIMK2 P53671 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806247 0.90 PDGFRB (0.52) NPC1RAB9AFLT3FAAHMAPK1
SCHEMBL2805561 0.88 KDR (0.51) NPC1RAB9AFAAHSMN1; SMN2PAK1
SCHEMBL2804018 0.88 NAMPT (0.48) NPC1RAB9AFAAH
SCHEMBL2806850 0.87 RAB9A (0.60) NPC1RAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL2805547 0.86 TRPV1 (0.56) SMN1; SMN2PAK1ALDH1A1MAPT
SCHEMBL2806010 0.86 TRPV1 (0.56) NPC1RAB9AFAAHLMNAPAK1
SCHEMBL2805002 0.86 PAK1 (0.60) NPC1RAB9AFAAHLMNAKDM4E
SCHEMBL2803952 0.86 TRPV1 (0.56) NPC1RAB9AHTTFLT3FAAH
SCHEMBL2804050 0.85 NAMPT (0.52) NPC1RAB9AMAPK1PAK1TP53
SCHEMBL2805744 0.85 PDGFRB (0.48) NPC1RAB9AFLT3FAAHMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 NPC1 205/4885RAB9A 1240/4885HTT 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.